The Medipattern Corporation

The Medipattern Corporation

October 03, 2011 09:00 ET

Medipattern Featured on WABC Radio Programs

Corporate Profile Minute and Money on the Mark Discuss Benefits of Visualize:Vascular™

TORONTO, ONTARIO--(Marketwire - Oct. 3, 2011) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, announced today that the Company will be featured on a Corporate Profile Minute heard on the nationally syndicated "Larry Kudlow Show", which airs Saturday mornings from 10:00 am to 1:00 pm EST on WABC Radio (AM770). The show offers listeners a tremendous wealth of insight and expertise to help better navigate today's evolving economic, investing, and political terrain.

In addition, Medipattern Corporation president and CEO, Jeff Collins, and Francis Porreca MD, FACS, RPVI, Director of the Weiler Division of Vascular Surgery at Montefiore Medical Center, will be interviewed on the Money on the Mark program hosted by Dale Jackson. The program can be downloaded from as aired on WMCA radio in New York on October 1st. In an excerpt from the interview, Dr. Porreca describes the problems caused by stroke as well as methods to identify at-risk patients to reduce the incidence of stroke in the at-risk population:

"Stroke is a tremendous problem in our country: 700,000 strokes occur annually and 165,000 deaths. It is the third leading cause of death after heart and cancer related causes. It is responsible for significant disability and loss of productivity especially for those who survive. Obviously it has tremendous health cost implications," comments Dr. Porreca. "Visualize has had a huge impact on our practice as vascular surgeons and we use it every day. Presently there are four tests that are used to look for obstructions in carotid arteries. [The first three tests, CTA, MRA, conventional angiography] all have inherent problems. They are invasive. They are expensive and they are associated with some toxicity because they require the administration of contract agents. The [fourth method] is the gold standard, the carotid duplex study, which is a combination of ultrasound and Doppler to give hemodynamic information. This also has some inherent problems; with ultrasound alone we are not able to precisely determine the exact amount of obstruction in the artery. What Visualize:Vascular has enabled us to do is to look at that artery in three dimensions using computer aided technology. We can then determine the reduction there is in the lumen and if there is a significant reduction, of course, the patient would benefit from having that artery operated on to remove the blockage in the artery which would reduce the incidence of stroke in these patients."

2011 Upcoming Events

Veith 38th Annual Symposium, Nov. 16 to 20 with partner Navix

RSNA 2011, Nov. 27 - Dec. 2 with partners TomTec and PenRad

About The Medipattern Corporation:

Medipattern® is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Medipattern uses its Cadenza™ technology to process images, finding the salient region of interest and presenting them in 2D and 3D formats that enhance the reader's perception. For more information, please visit the Company's website:

Medipattern® is a registered mark of The Medipattern Corporation. Visualize:Vascular™ is a trademark of the Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information